May Orfali, MD is the Medicines Development Lead for rare diseases at Pfizer’s Global Innovative Pharma Business Unit. Dr. Orfali is a pediatric hematologist/ oncologist with 20+ years of drug development experience in wide range of therapeutic areas, including hematology, pulmonary, metabolic disorders, oncology, women’s health and anti-infectives. Prior to Joining Pfizer Oncology group 8 years ago, she was the vice president of clinical development and medical affairs at Artisan Pharma developing a late stage asset for disseminated intravascular coagulation.

Steve leads the development and execution of the TS Alliance's scientific strategy through partnerships and conversations with stakeholders including individuals and families affected by TSC, basic and clinical researchers, healthcare providers, government agencies, and other non-profit organizations. As CSO since 2011, he has led the creation and growth of the TSC Preclinical Consortium to accelerate testing of potential new treatments and the Biosample Repository to share human TSC biosamples. Prior to joining the TS Alliance, Steve was a project leader responsible for driving global project teams toward new human proof-of-concept studies to re-purpose clinical-stage Pfizer compounds for new indications.

David Schubert is the Vice President of Regulatory and Quality at Stealth BioTherapeutics Inc. Previously, Mr. Schubert held positions at MediVector Inc., Logical Therapeutics Inc., Coley Pharmaceutical Group, Genzyme and Cubist Pharmaceuticals. Mr. Schubert has over 30 years of experience in biotechnology regulatory, rare disease drug development, quality, process development, and research and development and has chaired several Oligo-based Therapeutics Conferences co-sponsored by DIA and FDA.